Trends of Use of Anxiolytics and Hypnotics in Spain from 2000 to 2011

被引:0
作者
Vicente Sanchez, Maria Pilar [1 ]
Macias Saint-Gerons, Diego [1 ]
de la Fuente Honrubia, Cesar [1 ]
Gonzalez Bermejo, Diana [1 ]
Montero Corominas, Dolores [1 ]
Catala-Lopez, Ferren [1 ]
机构
[1] Agencia Espanola Medicamentos & Prod Sanitarios A, Div Farmacoepidemiol & Farmacovigilancia, Madrid 28022, Spain
来源
REVISTA ESPANOLA DE SALUD PUBLICA | 2013年 / 87卷 / 03期
关键词
Pharmacoepidemiology; Drug consumption; Drug utilization study; Anxiolytics; Hypnotics; Spain; GENERAL-POPULATION; BENZODIAZEPINE USE; MENTAL-DISORDERS; ANTIDEPRESSANTS; PRESCRIPTION; CONSUMPTION; MEDICATION; PREVALENCE;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: For years, anxiolytics and hypnotics have been one of the most prescribed drug classes in most developed countries. The main aim of this study is to explore the pattern of use of anxiolytic and hypnotic drugs during the period 2000-2011, comparing their growth with that of five european countries. Method: We performed an ecological and descriptive study of anxiolytics and hypnotics consumption in Spain. Consumption data were obtained from the databases of medications dispensed in community pharmacies and charged through official prescriptions to the totality of the Spanish National Health System. Annual and total-period consumptions were expressed in defined daily doses (DDD) per 1000 inhabitants per day (DDD/1000 person/day) by each treatment subgroup, active substance and attending the plasma half-life of the medication. Approximate comparisons were also made with some European countries. Results: The use of anxiolytics and hypnotics drugs was 56.7 DDD/1000 person/day in 2000 and 82.9 DDD/1000 person/day in 2011 (a +46.1% increase across the period). Lorazepam and alprazolam were the most used anxiolytics (20.5 and 15.6 DDD/1000 person/day in 2011, respectively), whereas lormetazepam was among the hypnotics (18.3 DDD/1000 person/day in 2011). In relative terms, hypnotics' lormetazepam and zolpidem increased their use by 103.3% and 85.1%, respectively; while anxiolytics' lorazepam and hydroxyzine increased 75.1% and 72.8%, respectively. In Spain (period 2003-2010), the total increase in the consumption of anxiolytics and hypnotics was +34.3%, with 24.0% for Portugal, 4.0% for Italy, but a reduction of -6.1% for France. Conclusions: A considerable increase in anxiolytics and hypnotics' consumption has occurred in Spain during the last decade, being the growth higher than that reported in other European countries.
引用
收藏
页码:247 / 255
页数:9
相关论文
共 25 条
[1]  
Adan Valero MA, 2010, SEMERGEN, V36, P372
[2]  
[Anonymous], 2011, SALES OF MEDICINAL P
[3]   BEFORE AND AFTER TRIAZOLAM - CHANGES IN THE CONSUMPTION OF HYPNOTICS IN SPAIN [J].
ARIAS, LHM ;
CARVAJAL, A ;
DEDIEGO, IM ;
DEABAJO, F .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (03) :289-290
[4]   Effects of Benzodiazepines, Antidepressants and Opioids on Driving A Systematic Review and Meta-Analysis of Epidemiological and Experimental Evidence [J].
Dassanayake, Tharaka ;
Michie, Patricia ;
Carter, Gregory ;
Jones, Alison .
DRUG SAFETY, 2011, 34 (02) :125-156
[5]  
de Gage SB., 2012, BMJ-BRIT MED J, V345, P345
[6]  
Delegacion del Gobierno para el Plan Nacional sobre Droga, 2013, ENCUESTA SOBRE ALCOH
[7]   Clinical factors influencing the prescription of antidepressants and benzodiazepines: Results from the European study of the epidemiology of mental disorders (ESEMeD) [J].
Demyttenaere, Koen ;
Bonnewyn, Anke ;
Bruffaerts, Ronny ;
De Girolamo, Giovanni ;
Gasquet, Isabelle ;
Kovess, Viviane ;
Haro, Josep Maria ;
Alonso, Jordi .
JOURNAL OF AFFECTIVE DISORDERS, 2008, 110 (1-2) :84-93
[8]  
Furtado C, 2010, ANALISE DA EVOLUCAO
[9]  
García del Pozo Javier, 2004, Rev. Esp. Salud Publica, V78, P379, DOI 10.1590/S1135-57272004000300007
[10]   The mental health risks of economic crisis in Spain: evidence from primary care centres, 2006 and 2010 [J].
Gili, Margalida ;
Roca, Miquel ;
Basu, Sanjay ;
McKee, Martin ;
Stuckler, David .
EUROPEAN JOURNAL OF PUBLIC HEALTH, 2013, 23 (01) :103-108